IDEXX 10-Q Details Q3 EPS of $4.01, $934M Nine-Month Net Income and $250M CoVetAI Deal
IDXX sits 34% above its 52-week low of $500.61 on elevated volume (3.5× avg).
Summary
IDEXX's Q3 10-Q confirms EPS of $4.01 on $1.214B revenue with margins expanding, nine-month operating cash flow of $1.063B, and quantifies the ~$250M CoVetAI acquisition closed September 15.
Key Events · Earnings and Guidance · IDXX
-
Q3 EPS $4.01 on $1.214B Revenue
Revenue rose 9.9% to $1,214,237 thousand from $1,105,239 thousand, with net income of $317,145 thousand and diluted EPS of $4.01 versus $3.40 a year ago.
-
Gross Margin Expands 110 Basis Points
Gross profit of $764,298 thousand was 62.9% of revenue versus 61.8% prior year, driven by VetLab consumable volume, mix and net price realization; income from operations rose 13.4% to $402,348 thousand.
-
Nine-Month Operating Cash Flow $1.063B
Net cash from operations reached $1,063,127 thousand, up $237,082 thousand year over year, funding $804,698 thousand of open-market buybacks and the CoVetAI acquisition.
-
CoVetAI Deal Priced at ~$250M
The September 15, 2026 acquisition carried total consideration of approximately $250 million including a $20 million estimated contingent payment, with $230 million allocated to goodwill and $25 million to technology and customer-relationship intangibles.
Analysis · IDXX · Life Sciences
The headline numbers were already out this morning via the 8-K and wires, but the 10-Q is where the full picture sits: Q3 revenue of $1.214B (+9.9%) with gross margin up 110 bps to 62.9%, and nine-month operating cash flow of $1.063B, up $237M year over year. It also puts hard numbers on the CoVetAI acquisition closed September 15 — roughly $250M including a $20M contingent payment, with $230M landing in goodwill — and confirms the buyback is running hard at $804.7M of open-market repurchases over nine months. The balance sheet stays conservative: $474M drawn on the credit facility against $773.2M of remaining availability and a 0.5-to-1 leverage ratio.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXX was trading at $670.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.9B. The 52-week trading range was $500.61 to $769.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.